Medical Design Briefs - October 2024 - 8

Nanosensors
DNA Sequencing
Roswell Biotechnologies, based in San
The abioSCOPE works by using nanofluidic technology combined with a digital immunoassay system. (Credit: Abionic)
real-time breath analyzer. This component
of the funding will be the first time
that the foundation has taken an equity
position in a breath diagnostics company.
The $1.5 million in grant funding to
support the identification of breath biomarkers
will be used across two projects:
TB: In partnership with the University
of Cape Town, South Africa, Owlstone
aims to identify a panel of onbreath
candidate VOC biomarkers that
differentiate TB subjects from healthy
controls and to develop breath diagnostic
approaches based on exploiting
the metabolic features of TB using in
vitro approaches.
HIV: Working with investigators from
Imperial College, UK, and Oxford University,
UK, Owlstone will analyze VOCs
from blood samples from subjects with
HIV and will work to identify a panel of
on-breath candidate VOC biomarkers
that correlate with HIV viral load.
In both areas, the data collected will
also be used to further populate Owlstone's
Breath Biopsy VOC Atlas.
In Vitro Diagnostics
Abionic's technology is particularly
valuable in emergency situations where
rapid diagnosis can be lifesaving, such
as in the detection of sepsis, allergies,
and cardiovascular conditions.
The
speed and portability of the company's
abioSCOPE® system enables healthcare
providers to make quicker decisions,
8
potentially improving patient outcomes
in critical care environments.
The abioSCOPE®
works by using
nanofluidic technology combined with a
digital immunoassay system. The platform
requires only a small blood sample,
which is placed on a disposable cartridge.
Inside the cartridge, nanofluidic
technology allows the sample to flow
through microscopic channels, where
specific biomarkers are captured and detected.
The results are then analyzed
and displayed on the abioSCOPE® device,
providing clinicians with critical information
within minutes.
In 2023, Abionic and biomedical
technology company LASCCO SA
signed a licensing agreement with
Fapon for the use of the pancreatic
stone protein (PSP) biomarker for sepsis
diagnosis in China. Under this
agreement, Fapon will develop and
commercialize PSP on its chemiluminescent
immunoassay (CLIA) analyzer
within the Chinese market.
This strategic partnership was designed
to remove barriers to early sepsis
diagnosis. Performing PSP testing on
high-risk individuals can flag potential
sepsis before the onset of clinical symptoms.
Early detection enables to rule in
/ rule out for critical care, to treat in a
timely manner which is tightly linked to
reduced risks of organ dysfunction and
improved survival rates, and to optimize
allocation of medical resources.
www.medicaldesignbriefs.com
Diego, CA, uses molecular electronics
for DNA sequencing and other applications
in biosensing. Their groundbreaking
work revolves around the development
of the Roswell Molecular
Electronics (ME) platform, which integrates
molecular electronics with semiconductor
technology to create precise
biosensors at the molecular level.
The company's technology applies
single-molecule detection, where electronic
sensors are used to directly measure
biological interactions in real-time.
The Roswell ME platform functions by
embedding molecules into an electronic
circuit. As these molecules interact with
biological samples, their electrical properties
change, and these changes are detected
and measured by the platform.
This approach allows for ultra-sensitive
detection of biological events, such as
DNA sequencing, at an unprecedented
scale and speed.
The primary focus of their platform
is to take DNA sequencing to a new level
by making it faster, more accurate,
and more accessible. By applying molecular
electronics, Roswell is looking
to overcome the limitations of traditional
sequencing methods, potentially
enabling advances in personalized
medicine and diagnostics.
According to the company, the company's
chip reads a multitude of molecules
- enzymes, DNA, RNA, proteins,
and small molecules - and for the first
time, provides direct real-time electrical
detection of single-molecule events
on-chip. Designed to overcome the enduring
scaling limitations of genomic
sequencing technologies, the Roswell
ME Chip Platform is designed to significantly
reduces genomic sequencing's
cost and complexity to advance
basic and translational research, precision
medicine, molecular diagnostics,
environmental surveillance, and digital
DNA data storage.
Blood Collection
YourBioHealth, formerly known as
Seventh Sense Biosystems, develops innovative
blood collection devices. Their
flagship product, Touch-Activated Phlebotomy
(TAP), is designed for virtually
painless and minimally invasive blood
collection. The device uses a combination
of microneedles and vacuum techMedical
Design Briefs, October 2024

https://www.medicaldesignbriefs.com

Medical Design Briefs - October 2024

Table of Contents for the Digital Edition of Medical Design Briefs - October 2024